announcements & circulars-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

investors

information disclosure

listing documents

financial reports

announcements & circulars

company presentation

corporate governance

stock information

ir contacts

email subscription

announcements & circulars

the announcement begins in december 2019

voluntary announcement - the combination therapy of kn026 and kn046 was granted orphan drug designation by the u.s. fda 2020-12-23
waiver from strict compliance with rules 3.28 and 8.17 of the listing rules 2020-12-23
voluntary announcement - bla accepted by the nmpa for kn035 in the treatment of msi-h/dmmr solid tumors 2020-12-21
change of joint company secretary and authorized representative and termination of the engagement of the chief financial officer and the board secretary 2020-12-07
monthly return of equity issuer on movements in securities for the month ended 30 november 2020 2020-12-04
next day disclosure return 2020-11-17
voluntary announcement - abstracts on preliminary positive results from the combination therapy of kn026 and kn046 for poster presentation at sitc 2020 2020-11-10
monthly return of equity issuer on movements in securities for the month ended 31 october 2020 2020-11-05
monthly return of equity issuer on movements in securities for the month ended 30 september 2020 2020-10-08
monthly return of equity issuer on movements in securities for the month ended 31 august 2020 2020-09-04